Limits...
Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation.

Gamble C, Dudley L, Allam A, Bell P, Goodare H, Hanley B, Preston J, Walker A, Williamson P, Young B - BMJ Open (2014)

Bottom Line: Funder requests for applicants to provide information on PPI and justification for its absence should be welcomed but further research is needed to identify the impact of this on its contributions to research.Comments on PPI by reviewers should be directional rather than state that an increase is required.Challenges facing applicants in initiating PPI prior to funding need to be addressed.

View Article: PubMed Central - PubMed

Affiliation: Department of Biostatistics, University of Liverpool, Liverpool, UK.

No MeSH data available.


Related in: MedlinePlus

Cumulative percentages of outline applications by disease/condition (PPI, patient and public involvement).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120322&req=5

BMJOPEN2014005234F3: Cumulative percentages of outline applications by disease/condition (PPI, patient and public involvement).

Mentions: Figure 3 and table 5 provide the data by year for specific conditions. Both of the diabetes trials were in children and were coded as paediatric, and there were no HIV/AIDS trials within the cohort. Figure 3 suggests declining rates of PPI in paediatric and mental health, with other areas including the general other category demonstrating an increase over time; however, as shown in table 5, the numbers in some categories were small.


Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation.

Gamble C, Dudley L, Allam A, Bell P, Goodare H, Hanley B, Preston J, Walker A, Williamson P, Young B - BMJ Open (2014)

Cumulative percentages of outline applications by disease/condition (PPI, patient and public involvement).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120322&req=5

BMJOPEN2014005234F3: Cumulative percentages of outline applications by disease/condition (PPI, patient and public involvement).
Mentions: Figure 3 and table 5 provide the data by year for specific conditions. Both of the diabetes trials were in children and were coded as paediatric, and there were no HIV/AIDS trials within the cohort. Figure 3 suggests declining rates of PPI in paediatric and mental health, with other areas including the general other category demonstrating an increase over time; however, as shown in table 5, the numbers in some categories were small.

Bottom Line: Funder requests for applicants to provide information on PPI and justification for its absence should be welcomed but further research is needed to identify the impact of this on its contributions to research.Comments on PPI by reviewers should be directional rather than state that an increase is required.Challenges facing applicants in initiating PPI prior to funding need to be addressed.

View Article: PubMed Central - PubMed

Affiliation: Department of Biostatistics, University of Liverpool, Liverpool, UK.

No MeSH data available.


Related in: MedlinePlus